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Objective.Uncertaintyanalysis(UA)isanimportantpartofsimulationmodelvalidation.However,literatureisimpreciseastohow
UA should be performedin the context of population-based microsimulation (PMS) models. Inthis expository paper, we discuss a
practical approach to UA for such models. Methods. By adapting common concepts from published UA guidelines, we developed a
comprehensive, step-by-step approach to UA in PMS models, including sample size calculation to reduce the computational time.
As an illustration, we performed UA for POHEM-OA, a microsimulation model of osteoarthritis (OA) in Canada. Results.T h e
resulting sample size of the simulated population was 500,000 and the number of Monte Carlo (MC) runs was 785 for 12-hour
computational time. The estimated 95% uncertainty intervals for the prevalence of OA in Canada in 2021 were 0.09 to 0.18 for
men and 0.15 to 0.23 for women. The uncertainty surrounding the sex-speciﬁc prevalence of OA increased over time. Conclusion.
The proposed approach to UA considers the challenges speciﬁc to PMS models, such as selection of parameters and calculation of
MC runs and population size to reduce computational burden. Our example of UA shows that the proposed approach is feasible.
Estimation of uncertainty intervals should become a standard practice in the reporting of results from PMS models.
1.Introduction
Computer simulation models are widely used in public
health research [1, 2]. Population-based microsimulation
(PMS) models are increasingly used to model possible eﬀects
of public health interventions at the population level [3–5].
Such models usually represent the population of a country:
incorporate multiple cohorts, and model births, deaths, and
migration [6–8]. Population-based models diﬀer from mod-
elscommonlyusedincohort-basedcost-eﬀectivenessstudies
that model a single cohort of patients [9]. Unlike macrolevel
simulation models (e.g., cell-based [10] or compartmental
models [11]), microsimulation (MS) models generate a life
history for every individual in a population [12, 13]a n d
provide population-level outcomes by aggregating the indi-
viduals’ event histories [14, 15].
In PMS models of chronic, noncommunicable diseases,
individuals can be treated as independent units (no inter-
individual interactions). Examples include models of breast
cancer [7, 16], stroke [6, 17], pulmonary disease [18], colon
cancer [19], diabetes [20, 21], and other chronic conditions
[5, 15]. MS models that incorporate interactions between
individuals, often referred to as agent-based models, have
beenusedtomodelinfectiousdiseases,suchasinﬂuenza[22]
and HIV [23]. The focus of the current paper is on non-
interactive PMS models of chronic diseases.
Uncertainty analysis (UA) plays an important role in
the validation of simulation models and interpretation of
their results [13, 24, 25]. The purpose of UA is to provide
uncertainty intervals around the mean estimate of one or
more outcomes [24, 26]. In UA, the model analyst attempts
to quantify the uncertainty around the outcomes that is2 Epidemiology Research International
propagated through the model from diﬀerent sources of
uncertainty [24–30]. These sources include Monte Carlo
(MC) error (i.e., random error), parameter uncertainty (i.e.,
uncertainty resulting from the fact that parameters used in
simulation models are estimated and not truly known [28,
29], structural uncertainty, that is, the uncertainty associated
with the choice of the statistical models [31], and possibly
other sources, such as the choice of the starting population
and sources of data that inform the model [25, 27].
In this paper, the term “parameter” refers to all possible
model inputs. Examples of parameters in PMS models are
those used to deﬁne the probability of events, such as disease
onset, death, or birth, or to describe the probability of
changes in the risk factors at the individual level, such as
changesinbodymassindex(BMI)orbloodpressure.Param-
eters can be classiﬁed into those derived directly from data
and those obtained from experts. Data-based parameters
can be further categorized into those estimated from a
sample and, therefore, subject to sampling uncertainty, and
those obtained from a population census (no sampling
uncertainty). Expert-derived parameters are characterized
by subjective uncertainty [13]. Further in the text, we will
discuss how to deal with each type of parameter in UA.
Several methods have been developed for capturing
uncertainty in the analysis of environmental risk assessment
models [32], cost-eﬀectiveness models in health economics
[33], and technology assessment models [34]. In environ-
mental risk assessment models [32], prediction of quantities
such as risks, exposures, and their eﬀect on human health is
critical for public policy decision making. Prediction is also
a major objective of PMS disease models [1, 8]. Providing
the distribution for the outcomes or uncertainty intervals
around the outcome estimates is an important step in ascer-
taining predictive validity of surveillance and risk assessment
models [30]. In cost-eﬀectiveness decision analytic models
[33], as opposed to predictive risk assessment models, policy
decisions aremadethroughcomparingcostandeﬀectiveness
of multiple scenarios by predeﬁned objective functions, such
asincrementalcost-eﬀectivenessratio(ICER)orincremental
n e tb e n e ﬁ t[ 33, 34]. An important diﬀerence between these
two types of models with regards to UA is that in predictive
models the goal is to estimate the uncertainty around a
projected health outcome under a given scenario, while in
decision analytic models one is usually interested in the
uncertainty around a relative measure comparing diﬀerent
scenarios [35, 36].
Probabilistic sensitivity analysis (PSA) is the term used
for UA in decision analytic models [34], while quantitative
UA is the term used in risk assessment and environmental
modeling [32]. UA is considered a necessary component of a
model-based analysis in almost all risk assessment modeling
guidelines [32] and recent decision analytic modeling guide-
lines [34]. For instance, sensitivity analysis (deterministic or
probabilistic) was cited as a requirement in the principles of
good practice for decision analytical modeling in healthcare
evaluations, developed by a task force from the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) and published in 2003 [37]. UA is also required
for health technology assessment modeling according to the
guidelines provided by the National Institute for Health and
Clinical Excellence (NICE) in the UK [34]. Performing UA
is important because in certain situations, it may change the
decision regarding the optimal scenario [35]. For example,
Griﬃn et al. [29] showed that in complex MS models with
nonlinear relations between the variables, interpretation of
the outcomes such as ICER could be biased if uncertainty
around the estimates is not considered.
UA is most informative when applied to complex models
that combine data from diﬀerent sources [4–7]. In addition
to providing uncertainty intervals around the outcomes, UA
is also used as a prerequisite for value of information analysis
in decision analytic models [34] or stochastic sensitivity
analysis (SA) in environmental models [37]. In both of
these approaches, the goal is to ascertain the contribution of
diﬀerentsourcesofuncertainty(e.g.,diﬀerentparameters)to
thetotaluncertaintyofthemodel[22,33,36,37].Asaresult,
critical regions of the parameter space can be located and
future research can be prioritized to obtain better estimates
of the key parameters and reduce the uncertainty [27].
Diﬀerences in the structure and intended applications
between PMS models and other types of simulation models
may aﬀect the methodology of UA. As the sources of
uncertainty in individual-level models diﬀer from those in
macrolevel models, the UA methods developed for macro-
level models [38] should be modiﬁed for use in PMS models.
Studies by O’Hagan et al. [39] discuss UA for individual-
level cost-eﬀectiveness models. However, their approaches
are not suited for models used for predictive purposes, such
as PMS models of chronic diseases used in health impact
assessment studies [1, 6, 7], or those used for population
projections [26]. A guideline for conducting UA in the con-
text of predictive models for risk assessment studies has
been published by the Environmental Protection Agency
(EPA) [40], but this guideline does not address the speciﬁc
problems that may arise while performing UA for PMS
models. In sum, no standard approach for UA in the context
of PMS models has been developed [13, 25].
The uncertainty associated with any given outcome in a
disease simulation model is typically a reﬂection of the com-
plex interplay among the model variables [12]. Due to this
complexity,estimatinguncertaintywithanalyticalapproach-
es is often impossible, and numerical methods, such as the
Monte Carlo (MC) method, are almost always required.
The MC method involves running the model many times
using randomly selected samples from the input parameter
space (i.e., parameter joint distribution) [32]. While the MC
method is the most common numeric approach to estimat-
ing parameter uncertainty [30, 32] in simulation models, in
its simplest (standard) form it is not suitable for MS models
due to the resulting computational burden [35].
Various techniques have been proposed to reduce the
computational time of UA in MS models. Cronin et al.
[31] used a response surface approach, which approximates
the simulation outcome as a linear function of the input
parameters. Others employed more complex approximate
functions, such as Gaussian and radial basis functions [41,
42]. The major limitation of these techniques is that the
assumptions of a speciﬁc response surface function may notEpidemiology Research International 3
holdin alltypesofMSmodels orevenfordiﬀerent outcomes
within one model [42]. Another approach is to perform
“guided” sampling, for example Latin hypercube sampling
(LHS) [31, 43] or orthogonal sampling [44]. However, these
sampling approaches do not reduce the model execution
time, which is the “bottleneck” of the total computational
time in UA [45]. O’Hagan et al. presented a method based
on the analysis of variance and discussed sample size calcula-
tions for UA in MS models [39].
In this paper we provide an overview of the main issues
and techniques in UA that are applicable to MS models. We
illustrate these techniques with an example in which UA is
performed for POHEM-OA [46], a PMS model of osteoar-
thritis in Canada.
2. Overview of UncertaintyAnalysis
2.1. Sources of Uncertainty. The sources of uncertainty vary
with the type of simulation model and the objectives and
design of a given study. Several sources have been discussed
in the literature [30, 44], with the emphasis on (i) MC error,
or ﬁrst-order uncertainty [2, 29, 36], and (ii) parameter
uncertainty, or second-order uncertainty [38, 39, 42]. MC
error is introduced when the starting values of the variables
in the model and the simulated events are assigned to each
individual using a stream of random numbers [9]. As such,
MC error reﬂects “unexplained” variation between the units
of a simulation model [32]. Parameter uncertainty arises
from random errors in the estimation of the input param-
eters [8, 30]. Parameter uncertainty exists in all manners
of simulation models. MC error, on the other hand, is not
a concern in macrolevel models, which do not attempt to
reﬂect stochastic variability between individuals [47].
Other types of uncertainty, including uncertainty in the
starting population [12] and structural model uncertainty
[16], have been studied. Structural uncertainty is associated
with the choice of model structure, including the statistical
models used, variables in the model, and the speciﬁed
relationships between the variables [31]. Examples of struc-
tural uncertainty commonly discussed in the literature are
uncertainty arising from alternative model types, such as
linear versus nonlinear dose response in environmental risk
assessment models [30] or the use of discrete event versus
state-based Markov models [16]. Structural uncertainty is
not considered further in the UA approach discussed in this
paper.
2.2. Uncertainty Analysis of Microsimulation Models. UA
in individual-level simulations needs to account for MC
error in addition to parameter uncertainty. This can be
accomplished by performing a nested analysis that iteratively
samples from the parameter space, calls the base model
(which itself is subject to MC error as it samples individuals)
withanewsetofinputparameters,andrecordstheoutcomes
[37]. Throughout this paper, this approach is referred to as
“theMCmethod”inthecontextofPMSmodels.Itshouldbe
noted that MC error is reducible by increasing the number
of simulated units or the number of simulation runs with
diﬀerent random seeds. However, parameter uncertainty is
ﬁxed and cannot be reduced [39].
There are two major issues when applying the MC
method to PMS models: (i) integrating MC and calibration
algorithm(s) inside the simulation model and (ii) reducing
the computational burden associated with the MC method.
Calibration algorithms are used extensively in PMS models
[13]. Ideally, the calibration algorithm should be integrated
into the UA, as discussed in Section 3.4. A Bayesian approach
that integrates calibration algorithms within the MC method
has been recently applied in MS disease models for estimat-
ing unknown parameters [48].
2.3. Computational Time in Uncertainty Analysis. In MS
models, a major burden in applying the MC method for
UA is the computational time. UA should be performed
using an outer loop of (n) model runs for the parameter
uncertainty and an inner loop for a population of (m) units
for the MC error [36]. To obtain an accurate estimate of
parameter uncertainty in macrolevel models, it has been
suggested that the number of model runs (n)( i . e . ,M Cr u n s )
should be large enough so that the uncertainty estimates
converge [29]. However, applying this recommendation to
MS models would make the UA computationally intractable,
as one run of such a model may take hours [41]. Two
approaches have been discussed in the literature for reducing
the computational time of UA in MS models: “emulator
based” [31, 41, 45] and “sample size based” [39].
Emulator-based approaches approximate the solution
space of the simulation model by preassumed functions
mapping the input parameters to the outcome. These
approximate functions predict the outcome of the main
simulation model instead of running the time-consuming
PMS at each instance of the MC process [31, 41, 45]. The
types of approximate functions used in MS disease models
include linear response function used by Cronin et al. [31]
for a model of prostate cancer, with the objective of investi-
gating the eﬀect of screening on prostate cancer mortality
rates, and Gaussian function for a patient-level model of
osteoporosis in Stevenson et al. [41].
The emulator-based method would save a signiﬁcant
amount of computation time at a costof losing precision due
to outcome approximation. Stevenson et al. [41]r e p o r t e d
that the required time for a single run of their model was
reducedfrom150minutesto“virtuallyinstantaneous”.How-
ever, this method requires the analyst to assume a certain
distribution for the outcome in order to be able to ﬁt a
responsesurface.Forexample,Croninetal.[31]usedalinear
approximate function and assumed Poisson distribution for
the number of prostate cancer-related deaths, which was the
outcome of choice for performing UA in their study. Com-
plexPMSmodelswouldneedaspeciﬁcresponsefunctionfor
eachoutcomeandthereisnoapriorireasontoexpectthatall
response functions have the same functional form. In other
words, one needs to use a diﬀerent approximate function for
each type of outcome in a single model.
Thesamplesizeapproachinvolvesﬁndingacombination
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of simulation runs that achieve a speciﬁed precision for
the outcome within a ﬁxed computational time [39, 45].
O’Hagan et al. [39] used analysis of variance (ANOVA) to
determine sample size in the case where two types of uncer-
tainty, MC error and parameter uncertainty, are considered.
Althoughtheirapproachwasoriginallydesignedfordecision
analytic models with incremental net beneﬁt as the outcome,
it can be used for other outcomes, including those typically
observed in PMS models. O’Hagan et al. [39] reported that
the computational demand was reduced by a factorof almost
36 (They mentioned that this claim is forthe incremental net
beneﬁt outcome and the resulting eﬃciency gain could be
diﬀerent for other outcomes.). The sample size approach is
simple to implement and does not require an approximation
function.
UA in MS models has been discussed in detail for cost-
eﬀectiveness studies with decision analytic purposes that
use speciﬁc type of outcome (i.e., cost-eﬀectiveness ratio
or incremental net beneﬁt) [47]. However, systematic pre-
sentations of UA for predictive PMS models with multiple
outcomes are lacking. In particular, there has been little
discussion of UA in the context of chronic disease models
withepidemiologicalorburden-of-diseaseoutcomes,suchas
those predicting the incidence and prevalence of a disease in
apopulation,itsimpactonmortalityandqualityoflife,orits
costs [3, 12]. In the following section we provide an overview
of the key steps in UA for such models.
3. Steps for Performing Uncertainty Analysis
3.1. Selecting the Outcomes. UA should be performed sepa-
rately for each outcome of interest. Due to their predictive
nature, most of PMS models are dynamic; that is, the
outcomes are time dependent. Typical examples of such
dynamic outcomes in public health applications include the
distribution of health determinants, disease incidence or
prevalence, mortality, quality of life, health care utilization,
and costs. The selection of the outcomes for UA depends on
the objectives of the study.
3.2. Selecting Parameters. After selecting the outcome of
interest (e.g., the prevalence of disease X over the next
N years), the next step is to screen the parameters and
select the relevant ones [45]. By “relevant”, we mean those
parameters that are likely to have signiﬁcant inﬂuence over
the selected outcome, as determined by the model analyst.
It is important to note that the uncertainty intervals from
UA will be conditional on the assumption that all parameters
not selected for UA do not introduce additional uncertainty.
Although ideally one would include all model parameters in
the UA, this is often impractical in complex models, such
as many PMS disease models, that may include hundreds of
parameters [1, 2, 5, 7].
Tools for determining parameter inclusion range from
qualitative approaches, such as scrutinizing the model’s con-
ceptual diagram and investigating its major components, to
morequantitativeapproaches,suchasparameterprioritizing
[45] and tornado diagrams [37, 47]. Scrutinizing the model,
beginning with its major components, helps in identifying
the most important parameters, eliminating the irrelevant
ones, and identifying possible dependencies between the
parameters.
Diﬀerent components of the simulation model, such as
demographic, disease, and intervention components, need
to be examined to ascertain which parameters to include in
the UA. The data sources for the parameters should be con-
sidered as well. For example, the demographic component
may include the parameters describing the distribution of
age and sex in the population, as well as birth and death
rates over time. These parameters are often derived from
vital statistics or large population databases and may be
excluded from UA due to minimal uncertainty. However, if
any of the above processes are modeled from a sample, then
sampling variability should be incorporated into the UA.
For example, a CISNET model for breast cancer [16] used
Surveillance, Epidemiology, and End Results (SEER) [51]
to estimate all-cause and cancer-speciﬁc mortality rates by
age and sex. Because the SEER database is very large, the
sampling variability of the SEER-derived mortality rates is
likely small, but may not be negligible. Further analyses,
discussed later in this section, may be needed to determine
the inclusion of such parameters in the UA.
In making decisions about which parameters to include,
the analyst needs to take into account possible discrepancies
between the population being simulated and the base pop-
ulation from which the data have been gathered. If the
calibration has been performed to ﬁll in this discrepancy,
the parameters used in the calibration should be included in
the UA (unless they are estimated from a large population
data or census data). In addition, the calibration algorithm
itself should be integrated into the UA process. For example,
in POHEM-OA [46], a PMS model of osteoarthritis in
Canada, the baseline incidence of osteoarthritis (OA) was
estimated from a population-based administrative database
in British Columbia (BC), Canada, that includes healthcare
data for almost all residents of the province (Table 1)[ 52].
To simulate the incidence of OA in Canada, a calibration
algorithm is needed to obtain the incidence of OA in the
reference category of BMI, given the BMI hazard ratios and
the distribution of BMI in the population. The calibration
algorithm uses a direct search method to match the marginal
distribution of incidence in the province of BC to that of
the simulated population of the Canada [52] by changing
the baseline distribution until the target value is reached for
every age/sex category within a small acceptable distance. We
will discuss the details of implementing calibration into UA
in Section 3.4.
ParametersindiseasecomponentsofthePMSmodelsare
mostly coeﬃcients in statistical models used to determine
the distribution of risk factors in the population, both
the baseline distribution and the dynamics of how risk
factors change through time and space, in addition to the
coeﬃcients used in modeling the probability of event, mostly
through relative risks (or hazard ratios) associated with the
risk factors. For example, in POHEM-OA [46], the baseline
distribution of body mass index (BMI), a risk factor for
OA, was derived from the Canadian Community Health
Survey (CCHS) [50]( Table 1). The dynamics of how BMIEpidemiology Research International 5
Table 1: Components and parameters of a simpliﬁed version of
POHEM-OA
∗ that was used for the uncertainty analysis example.
Demographic components
Age distribution in 2001∗∗
Sex distribution in 2001∗∗
Province of residence distribution in 2001∗∗
Birth and mortality rates by age and sex over time#
Migration##
Disease components
(i) Baseline parameters
BMI distribution in 2001∗∗
Incidence of OA in 2001 by sex and 5-year age groups
Reference (“baseline”) hazard rates of OA§
Prevalence of OA in 2001 by sex and 5-year age groups§§
(ii) Risk factors model
Change in BMI over time§∗
(iii) Disease incidence
Eﬀect of BMI on incident OA by sex§#
∗POHEM-OA:PopulationHealthMicrosimulationmodelforosteoarthritis
(OA) [46]. ∗∗Observed in Canadian Community Health Survey (CCHS-
2001) [50]. #Projected mortality in Canada by age and sex from Statistic
Canada. ##Migration data obtained from Statistics Canada projections.
BMI: weight/height2. From administrative data in BC [52]; OA is
deﬁned as at least 2 visits to a health professional within 2 years or 1
hospitalization with the ICD-9 code 715. Incident cases in 2001 are iden-
tiﬁed after excluding prevalent cases prior to 2001 using a 10 year run-in
period[46]. §Obtained numerically using calibration to match the marginal
distribution of incidence in BC administrative data. §§Obtained as the ﬁnal
stable prevalence from a simulation of the Canadian population over a
50-year horizon, under constant age-speciﬁc incidence rates. §∗Obtained
from a linear regression model including age, sex, province, education, and
prior BMI. §#BMI was categorized into 4 standard categories (see Table 3).
The eﬀect (hazard ratio) for each level of BMI is obtained from a survival
regression model using longitudinal NPHS data (two cycles: 2000 and 2002)
[49], separately for men and women.
changesintime andin diﬀerentprovinceswasmodeled from
the longitudinal National Population Health Survey (NPHS)
[49]. Parameters in disease component can be excluded from
UAiftheyareobtainedfromfullpopulationdata,suchasthe
census or vital statistics. However, this is often not the case
for the parameters used in modeling probability of events
(e.g., relative risks associated with risk factors) as they are
mostly estimated from sample data [27]. For example, the
coeﬃcients in Framingham equations, commonly used for
modeling the risk of cardiovascular disease in simulation
models, come from the Framingham sample [53] and, there-
fore, are subject to sampling variation.
Another group of parameters that should be considered
forUAarethosedescribingtheeﬀectsofhealthinterventions
[54]. For example, in the chronic disease prevention (CDP)
model [55], a PMS model for evaluating interventions for
reducing obesity, the eﬀects of physician counseling was
translated into reductions in the percentage of total choles-
terol intake, BMI, and systolic blood pressure. Another
example is the parameters describing the eﬀects of a screen-
ing program on quality adjusted life years (QALYs) and
excess mortality in a CISNET model of breast cancer [16].
Whenever the outcome chosen for the UA (in Section 3.1)
is related to the intervention, the best practice is to include
the “intervention” parameters into UA, as most of these
parameters are estimated from sample data and the uncer-
tainty associated with them signiﬁcantly aﬀect the outcome
uncertainty.
The tornado diagram is a useful tool for prioritizing the
parameters in the initial steps of UA [47]. A tornado dia-
gram represents the results of multiple univariate sensitivity
analyses in which one parameter is changed at a time and
the highest and lowest value of the outcome are determined.
The parameters are then sorted according to their impact
and presented graphically, often as a horizontal bar diagram
[25]. Tornado diagrams do not consider the interactions and
correlations between parameters. Figure 2 shows an example
ofthetornadodiagramforthePOHEM-OAmodeldiscussed
in greater detail later in Section 4.
3.3. Assigning Distributions to Parameters (or Using Boot-
straps). For the selected parameters, the model analyst
should either assign a distribution or use a bootstrapping
approach to be able to apply the MC method and get
the uncertainty interval for the outcome, as discussed in
Sections 3.4 and 3.5. Parameters in the simulation models
maydeﬁnetheriskofanevent,suchashazardsratios,relative
risks, odds ratios, and transition probabilities of events,
or estimate the dynamic changes in a continuous variable
(e.g., regression coeﬃcients for modelling BMI changes over
time [46]). Parameters may be estimated directly from data,
drawn from literature, or based on expert opinions. For
parameters estimated from data using parametric (and
semiparametric) statistical models, the distribution can be
obtainedfromtherelevantstatistics.Thecommonregression
models, such as the parametric multiple linear, logistic, and
semiparametric Cox proportional hazards models, utilize a
speciﬁc distribution for the outcome [47].
Incorporating uncertainty into the risk of an event
depends on the structure of the model. In some predictive
MS models, risk functions for events use event-history mod-
eling [56, 57] as opposed to memoryless (Markovian) states
[9, 47, 58]. Event-history modeling equations represent the
behaviour of an individual through dependence on his/her
simulated past. For example, in the LifePaths model [59], a
PMSmodeloftheCanadianlabourforce[60],thetimingofa
child’sbirthisdeterminedbythetimingofparents’marriage,
the time since the previous births in the family, and the age
oftheparents.Incontinuous-timeevent-historymodelswith
hazard functions, an asymptotic lognormal distribution can
be assigned to hazard ratios [47], while a normal (Gaussian)
distribution can be assigned to the log transformation of the
relativeriskoroddsratio,underthelargesampleassumption
[61].
Regression coeﬃcients used in modelling changes of risk
factors over time are another types of parameter in PMS
models. For instance, coeﬃcients in the dynamic models
of BMI changes in POHEM include age, sex, place of
birth (time-invariant covariates), and socio-economic status
(time-dependent covariate), as well as previous levels of BMI
[46].Forsuchcomplexmodels,theuncertaintyanalystneeds6 Epidemiology Research International
to estimate the variance of the coeﬃcients of the regression
models (or use bootstrap weights for the outcome) [60].
InMSmodelsutilizinglongitudinaldata,eventsareoften
deﬁned based on hazard functions and waiting time distri-
butions [61, 62]. The waiting time distribution can be expo-
nential (for ﬁxed hazards) [46], Weibull (for time-dependent
hazards) [47, 61], or Gompertz (for time-dependent hazards
with additional complexity, such as those for tumour growth
modeling in cancer models [16]). Transition probabilities
can be converted into hazards for use in continuous-time
models [5, 62]. Other examples of parameter distributions
often used in health simulation models include the beta
distribution (e.g., for modeling cost data)[55], the gamma
distribution (e.g., for modeling quality-adjusted life years)
[47], and the Poisson distribution for modeling event counts
[31].
For parameters drawn from the literature, only the mean
and its 95% conﬁdence interval are often reported, without
the actual distribution. In such cases, method of moments
[47] can be used. Alternatively, the analyst needs to assume a
speciﬁc distribution appropriate for a given parameter. The
variance of the parameter can then be estimated from the
conﬁdence interval reported by the authors [47].
Parametersestimatedbyexpertopinionareoftenignored
in UA. This may result in a substantial underestimation of
the true uncertainty [27]. It is often possible to assign upper
and lower bounds to the estimated parameters using experts’
judgment, for example, where there are biological limits
to a disease process (e.g., tumour growth) or limits to an
epidemiologicalparametersuchasprevalenceorcasefatality.
In these cases, the distribution could be quantiﬁed by a
uniform, triangular, or trapezoidal distribution by assigning
lower and upper bounds in addition to the mode of the
distribution, or lower and upper bounds on the mode in
case of a trapezoidal distribution [63]. General distributions
such as the generalized beta distribution family and the
Johnson translation system of distributions are among the
best choices in case several data points have been selected in
theliteratureorgatheredfromexpertopinions[63].Another
approach to assigning distribution to parameters estimated
from expert opinion is the Bayesian method [64]. A key task
inapplyingthismethodistheexpressionofexpertopinionin
the form of a (prior) probability distribution [64]. An exam-
ple is the Sheﬃeld elicitation framework (SHELF) developed
by Garthwaite et al. [64], elaborating steps to construct a
probability distribution for the parameters expressed by a
group of experts.
For parameters estimated from nonparametric mod-
els, the uncertainty analyst should use bootstrap methods
instead of sampling from a distribution. Bootstrap method
provides an easier approach for estimating uncertainty for
those parameters whose distribution cannot be identiﬁed.
It can also be used to reduce the computational diﬃculties
in sampling from a parametric distribution for parameters
estimated from surveys that use a complex sampling design
involving stratiﬁcation and clustering [65]. In both cases,
bootstrap methods sample with replacement from the
original data [66]. As an example, the National Population
HealthSurvey(NPHS)[49],alongitudinalhouseholdsurvey
conducted by Statistics Canada every two years since 1994,
provides bootstrap weights for users to estimate the variance
of their estimators, such as regression coeﬃcients. We will
implement this type of bootstrapping in Section 4.
Accounting for Correlations between Parameters. After select-
ing the parameters for UA, the analyst needs to examine
the relationship between the parameters to ensure their
correlations are taken into account. The analyst can identify
thecorrelationsbetweenparametersbyexaminingthemodel
diagram and reviewing the parameter estimation process
[25]. For example, relative risks associated with diﬀerent
levels of an ordinal risk factor are often correlated. As
illustrated in Figure 1, in the POHEM-OA model, the hazard
ratios of OA incidence for four diﬀerent BMI categories are
interdependent. Such dependence should be reﬂected in this
step of the UA, through assigning a joint distribution using
covariance matrices (often estimated from the regression
model). When bootstrap methods are used, parameter inter-
dependence will be inherently reﬂected in the distribution of
the outcome.
3.4. Monte Carlo Method. This step involves applying the
MC method to calculate the uncertainty intervals for the
mean outcome of interest. This step involves sampling from
the assigned distribution or using bootstrap methods as
discussed in Section 3.3.
Sampling Approach. For those parameters that have been
assigned a distribution, we need to specify the sampling
a p p r oa c h ,a si twi lla ﬀect the uncertainty intervals of the out-
come. The sampling approach should be both eﬀective, to
encompass the entire distribution of the parameter, and
eﬃcient, to sample only the required number of points.
There are several sampling approaches for the MC method
[45]. One of the most eﬀective is the Latin hypercube
sampling(LHS)[31,43].LHSisaparticulartypeofstratiﬁed
sampling,whichsamplesfromtheequallyprobablesegments
of the parameters distribution. It is designed to provide
a comprehensive coverage of the parameter space. More
complex sampling approaches include orthogonal sampling
and adaptive kriging sampling [44, 45]. Although LHS is
not the most eﬃcient sampling approach, as it samples
more points than necessary, it is commonly used due to its
eﬀectiveness. It samples enough points within a reasonable
computational time and is more eﬃcient than random uni-
form sampling.
A common sampling technique is to generate a uniform
random number (between 0 and 1) through one of the
existing random number generator algorithms [61]( e . g . ,
pseudorandom number generators are among the most used
methodsthatdeterministicallyperformseriesoftaskstogen-
erate statistically sound (uniform) random numbers [12]).
Then, using the inverse of the cumulative density function
(CDF),knownasthequantilefunction,oneﬁndsarealvalue
of the parameter.
For correlated parameters, an appropriate joint distri-
bution should be speciﬁed, as discussed in Section 3.3,a n dEpidemiology Research International 7
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Figure 1: Diagram of the simpliﬁed version of the POHEM-OA used for the uncertainty analysis example. POHEM-OA: Population Health
Microsimulation model for osteoarthritis (OA) [46]. Rectangles inside the ﬁgure are data sets used for estimation of parameters; ﬁrst in top
left: NPHS 1994–2004: National Population Health Survey, a longitudinal household survey by statistics Canada with a sample of size of
over 17,000 persons that started in 1994 [49], 5 cycles (1996–2006) have been used in BMI trajectory model and two cycles (2000–2002)
used in estimation of relative risks (hazard ratios) of OA. ∗∗Rectangle in the bottom left corner: CCHS 2001 (Canadian Community Health
Survey [50]) used for generating the starting population for the microsimulation with characteristics listed on the left column of the ﬁgure.
∗∗Rectangle inthe bottom right corner: Pop-data BC (population data BC [49]): administrative billing data for the province of BC including
data for >98% residents of BC from 1994–2003, used for estimating incidence of OA.
Prevalence of OA among females in 2021
0.1 0.15 0.175 0.2 0.25 0.3
BMI trajectory model parameters
Hazard ratio of OA for (30 > BMI > 25)
Hazard ratio of OA for (25 > BMI > 18.5)
Hazard ratio of OA for (BMI >30)∗
Figure 2: Tornado diagram for prevalence of osteoarthritis among females in year 2021—predicted by POHEM-OA. POHEM-OA: Popu-
lation Health Microsimulation model for osteoarthritis (OA) [46]; ∗each of the hazard ratios parameters on the left have been varied based
on the upper and lower limits of the estimated 95% CI shown in Table 3.
the sampling technique should be adapted accordingly [47].
In general, if the marginal univariate distributions of the
parameters and the correlation between them are known,
sampling from a multivariate distribution can be performed
using the multivariate normal copula with matrix algebra
(e.g., Cholesky decomposition) [47].
Calibration in UA. Calibration is a technique commonly
used in population-based models with predictive goals when
direct estimation of a given parameter is not possible and
model parameters are selected so that the model reproduces
observed results [67]. At each step of the MC sampling,
calibration should be performed with the new (random)
sample of the parameters, generated in previous step. After
the calibration procedure converges, the simulation model
should be run with the calibrated parameter. As a result, the
calibration procedure should be implemented inside the UA
and be executed at each run of the MC method.
Determining the Number of MC Runs and Population Size.
The computational burden of UA can be reduced by the
appropriate choice of the simulated population size (m)a n d
number of simulation runs (n). As discussed in O’Hagan
et al. [39], the variance of the mean outcome based on the
simulation results is given by the formula:
 σ2 =

 σ2
1
mn

+
 σ2
2
n
. (1)
In (1)a b o v e , σ2
1 reﬂects the MC error and  σ2
2 reﬂects
the parameter uncertainty (and it is assumed that patients8 Epidemiology Research International
outcomes are independent). The goal of the sample size
approach is to ﬁnd values of (m)a n d( n) such that a
desired precision level d is achieved; that is, ( σ2 = d)i s
achieved given a ﬁxed amount of computation time. The
computational time is assumed to be linear in terms of both
population size (m) and number of MC runs (n)( i . e . ,K =
mn,w h e r eK is measured in terms of number of individuals
that can be simulated in the available time.). Since  σ2
1 and  σ2
2
are unknown, the solution is obtained in two steps. In the
initial step, a small number of simulation runs are completed
and  σ2 and  σ2
1 are estimated from the outcome while  σ2
2 is
obtained by subtraction using (1). Next, in the main step, (1)
is solved for (n)w i t h( mn) replaced by K and  σ2 replaced
by (d) to obtain the lowest number of computational runs,
(n∗), that satisﬁes the computational time and precision
constraints. The corresponding value for the population size,
(m∗), is then obtained from the constraint K = m∗n∗.N o t e
that this procedure typically does not generate the optimal
choices for (m∗)a n d( n∗). The ﬁnal estimated number of
MC runs is the smallest number that can produce the desired
precision level for a given computational time.
As discussed in O’Hagan et al. [39], in order to gain the
maximum information for estimating uncertainty intervals
in a ﬁxed amount of computational time, one should use
a relatively small population size and a large number of
simulation runs. In other words, the optimal design is to
simulate a small population over and over again using a large
number of sample points from the joint distribution of the
parameters.
3.5. Constructing the Empirical Distribution of the Outcome.
In the ﬁnal step of the UA, the analyst constructs the
cumulative distribution function(CDF) ofthe outcomeafter
applying the MC method with a population size of (m)a n d
number of MC runs of (n) calculated using the “sample
size” approach discussed in the previous section. The 95%
uncertainty interval of the outcome is constructed using the
quantile function based on the CDF of the outcome being
analyzed. The results of the UA, often represented by 95%
uncertainty intervals, should be presented as conditional on
the assumptions of the model.
4. Exampleof Uncertainty
AnalysisinPOHEM-OA
We provide an example of the UA approach outlined in
the previous section, using a simpliﬁed version of POHEM-
OA, a PMS model of osteoarthritis in Canada (Figure 1)
[46]. POHEM-OA is a complex model, featuring a large
number of parameters [46]. In our example, the focus is on
modeling the incidence and prevalence of OA. Table 1 lists
the parameters used in this example and the data source
for each. Table 2 describes the steps of the proposed UA
approach and the corresponding steps of the POHEM-OA
example. In the ﬁrst step of the proposed UA (Section 3.1),
we selected the gender-speciﬁc prevalence of OA in Canada
from 2001 to 2021 as the outcome of interest. In the
second step of the UA (Section 3.2), we ﬁrst investigate the
conceptual model diagram shown in Figure 1. Most of the
parameters shown in Figure 1 are not included in the UA.
ParametersestimatedfromtheCanadianCommunityHealth
Survey (CCHS-2001) [50], a national survey with a very
large sample size (N = 130,000), and parameters obtained
from provincial administrative data in BC [52]a r ee x c l u d e d
because their variance is considered to be small.
For the selected parameters, a Tornado diagram has been
constructed as shown in Figure 2. Two types of parameters
have shown the highest impact on uncertainty in univariate
analysis and were included in the ﬁnal UA analysis. These are
(i) the hazard ratios (HR’s) for the eﬀect of diﬀerent levels of
BMIonOAincidenceand(ii)theregressioncoeﬃcientsused
in modeling BMI progression in the simulated individuals
over time. The HR’s for BMI categories have been estimated
from the National Population Health Survey (NPHS) [49],
a longitudinal survey in Canada with a sample of size of
over 17,000 persons that started in 1994. Two cycles of
NPHS were used for the analysis of HR’s in POHEM-
OA. The HR’s have been estimated using an exponential
survival regression model [46]. The point estimates and
95% conﬁdence intervals for the parameters are shown in
Table 3 and the correlation matrices are shown in Table 4.
The model for BMI progression is based on 6 cycles of the
NPHS (1996–2006) [49] and includes BMI history (up to 4
pastBMIvalues)andothercovariatessuchasage,sex,region,
education, and income. The model was stratiﬁed by age, sex,
andBMI,resultingin112regressionmodels(28age-sex-BMI
strata and 4 autoregression models).
In the third step of the proposed UA (Section 3.3), we
used a multivariate lognormal distribution for the hazard
ratios. In the fourth step of the proposed UA (Section 3.4),
Latin hypercube sampling (LHS) has been used to sample
from the multivariate HR’s distribution with the given
correlation matrices (Table 4), translated into covariance
matricesfortheLHS.Thesecondsetsofparametersarethose
usedintheBMIprogressionmodels.Toavoidthecomplexity
of assigning distributions to a large number of models,
we used the bootstrap weights developed for the NPHS by
Statistics Canada [49]. For each BMI progression model
(age and sex speciﬁc), we derived eight sets of parameter
estimates, meaning that each set of parameters represents a
sample from the underlying joint multivariate distribution
for the covariates of the BMI model. At each run of the
UA, we randomly selected one of these samples based on
each person’s age/sex, in addition to randomly sampling
the hazard ratio of the OA event from a multivariate
lognormal distribution. POHEM-OA calibrates the baseline
incidence of OA using population data from the province
of British Columbia [52]. As discussed in the calibration
step of Section 3.4, we have automated the calibration
algorithm and integrated it with the MC method, so that
for each sample of HR’s, calibration is performed to get the
(calibrated) baseline incidence rate; then, repetitive runs of
the simulation model are performed by applying the MC
method.
TodeterminethenumberofMCrunsandthepopulation
size (last step of Section 3.4), we used the method discussed
by O’Hagan et al. [39]. The number of MC runs is calculated
as a function of precision level (set to 0.01), computationalEpidemiology Research International 9
Table 2: Proposed steps for uncertainty analysis in population-based microsimulation models and corresponding steps for POHEM-OA
uncertainty analysis example.
Steps for performing uncertainty analysis in population-based
microsimulation models Steps for uncertainty analysis in POHEM-OA
Step 1. Selecting the outcome Sex-speciﬁc prevalence in (2001–2021)
Step 2. Establishing the UA list of parameters
(1) Hazard ratios for each BMI-category
(2) BMI progression
Step 3. Assigning a probability density function to parameters
(or use bootstrap sampling)
(1) Lognormal distribution for hazard ratios with sex-speciﬁc
correlation matrices
(2) Using 8 alternative regression models using bootstrap weights
from NPHS§ (1996–2006)
Step 4. Applying Monte Carlo method
(i) Select a sampling approach (or use bootstrap sampling).
(1) Latin hypercube sampling
(2) Random sampling with replacement (among eight alternate sets
of parameters)
(ii) Implement calibration into MC method.
Calibrate on incidence by age and sex; implement the calibration
algorithm into the MC method, using squared error criteria for
convergence.
(iii) Calculate n∗, m∗ for precision level d.
Result: m0 = 20,000,000 population size; n0 = 5 (for the initial run);
m∗ = 500,000 people; n∗ = 785 MC-runs for d = 0.01; for 12-hour
run of a PC with 12GB memory, CPU = i7-980 Intel, 3.3GHz.
Step 5. Constructing the outcome distribution Please see Figure 3.
§NPHS: National Population Health Survey, a longitudinal household survey by statistics Canada with a sample of size of over 17,000 persons that started in
1994 [49].
Table 3: Point estimates and 95% CI for hazard ratios of osteoar-
thritis in POHEM-OA∗, estimated from the NPHS∗∗ (2000–2002);
reference category: normal weight (18.5 ≤ BMI < 25).
Male (95% CI) Female (95% CI)
Under weight
(BMI < 18.5) — 0.33 (0.02–0.4)
Normal weight
(18.5 ≤ BMI < 25) 1 (ref) 1 (ref)
Over weight
(25 ≤ BMI < 30) 1.07 (0.68,1.74) 1.76 (1.14–2.62)
Obese
(BMI ≥ 30.0) 1.69 (1.03,2.81) 2.03 (1.34,2.96)
∗POHEM-OA:PopulationHealthMicrosimulationmodelforosteoarthritis
(OA) [46]; ∗∗NPHS: National Population Health Survey, a longitudinal
household survey by statistics Canada with a sample of size of over 17,000
persons that started in 1994 [49].
time (set to 12 hours), and initial estimates of the MC
error and parameter uncertainty. The initial estimates were
obtained by running the model 5 times with a sample size
of 20 million (Each POHEM run that simulates the entire
Canadian adult population of around 20 million takes about
35 minutes on a PC with 12GB RAM and 3.33GHz. CPU,
Intel i7-X980.). Applying the formulas from O’Hagan et al.
[39], as described in Section 3.4, we obtained (n = 758) and
(m = 500,000). Approximately 10–15 iterations were needed
for calibration before each main run, and each run with
population size of (m = 500,000) took about 50 seconds.
It should be noted that without applying the sample size
approach by O’Hagan et al. [39], to get the same precision
level with a sample size of 20 million, we would need to run
the model about 400 times and it would take about 12 days
of run time (an almost 25-fold increase in time eﬃciency).
Although increasing the population size (m) or increasing
the number of MC runs (n) increases the precision level of
the mean estimate (and consequently the precision of the
resultant uncertainty interval), increasing (n)h a sam u c h
higher impact on the precision level than increasing (m).
The reason is that the variance of the mean estimator ((1)
in Section 3.4) is a function of (m)a n d( n), where (n)a ﬀects
both terms on the right-hand side of the equation, and (m)
only aﬀects one term, as discussed in O’Hagan et al. [38].
That is why running the model 400 times with a sample of 20
million produces the same precision as running the model
785 times with a sample of 500,000.
Result of the UA is shown in Figure 3. The estimated
95% uncertainty intervals for the prevalence of OA in
Canada in 2021 are 0.09 to 0.18 for men and 0.15 to 0.23
for women if we include both MC error and parameter
uncertainty of the hazard ratios of OA associated with
diﬀerent categories of BMI as well as BMI trajectory model
parameters. These results are based on the assumption that
uncertainty in other parameters shown in Table 1 can be
ignored.Thisassumptionwouldbereasonableforparameter
estimated from large population-based datasets, such as
provincial administrative data [52], but not for parameters
estimated from smaller studies, as discussed in Section 3.2.
The uncertainty contributed by the parameters estimated
from the CCHS (sample size 130,000) can be assumed to
be small, compared to those estimated from the NPHS
[49] (sample size of 17,000), and has been ignored in this10 Epidemiology Research International
Table 4: Correlation matrix for hazard ratios of osteoarthritis in POHEM-OA∗, estimated from the NPHS ∗∗(2000–2002); reference
category: normal weight (18.5 ≤ BMI < 25), shown for male (female) in the upper (lower) triangular part of the matrix.
BMI < 18.5 18.5 ≤ BMI < 25 25 ≤ BMI < 30 BMI ≥ 30.0
BMI < 18.5 1 0.5125 0.5362 (Ref)
18.5 ≤ BMI < 25 0.6234 1 0.5405 —
25 ≤ BMI < 30 0.6325 0.5812 1 —
BMI ≥ 30.0 (Ref) — —
∗POHEM-OA: Population Health Microsimulation model for osteoarthritis (OA) [46]; ∗∗NPHS: National Population Health Survey, a longitudinal
household survey by statistics Canada with a sample of size of over 17,000 persons that started in 1994 [49].
example. If the uncertainty associated with other parameters
were included in the analysis, the UA interval would have
been equal or larger.
5. Discussion
Complex MS models are increasingly used in modeling
chronic diseases [1, 4–9, 17–21]. UA is critical to the valida-
tion of such models and interpretation of their results [24–
30]. There is a growing literature on the methods of captur-
ing uncertainty in quantitative policy analyses [30, 68]. The
US Environmental Protection Agency [40] and the National
Academy of Science [32] identify MC methods as preferred
approaches to quantifying uncertainty in environmental risk
assessment models.
T h eg o a lo fU Ai nM Sm o d e l si st op r o v i d eu n c e r t a i n t y
intervals around each outcome. Applying the MC method
to estimate the variance of the mean outcome is the core
of the UA process. Several guidelines discuss the steps in
performing UA to capture the uncertainty in risk assess-
ment models [32] and cost-eﬀectiveness models in health
economics [34]. However, there is a gap in the literature
regardingtheapplicationofMCmethodstoUAinpredictive
PMS models. To our knowledge, no UA guidelines have been
developed speciﬁcally for MS models that incorporate health
outcomes other than cost-eﬀectiveness ratios and simulate
real populations rather than hypothetical cohorts.
In this paper we suggest an approach for estimating
the uncertainty intervals for PMS models that implicitly
takes into account the complexity of the model, number
of parameters, model calibration, and correlations among
the parameters. We have outlined the steps involved in per-
forming UA, including a practical approach to lowering
the computational demand, developed by O’Hagan et al.
[39]. The key idea that led to the sample size approach of
O’Hagan et al. [39] is the trade-oﬀ between the number
of MC runs and the population size. In fact, by increasing
the number of MC runs while decreasing the population
size, one can increase the precision level of the resultant
uncertaintyintervalforaﬁxedcomputationaltime[39].This
resulthasbeendiscussedinbothRutteretal.[13]andGriﬃn
et al. [29] for the optimal design of the UA. The major
assumption is that the computational time is linear in m and
n.
In contrast to the optimal design, UA in MS models is
often performed by running the model a small number of
times, due to the computational time constraint [13, 29].
However, this practice is not acceptable due to the low
precision of the resultant intervals. On the other hand,
ignoring ﬁrst-order uncertainty (i.e., MC error) would result
in a biased, and too small, uncertainty estimate of the
outcome in MS models. The approach applied in this paper
canbeusedtoreducethecomputationtimewhiletakinginto
account both the ﬁrst- and the second-order uncertainty.
Alternatively, one can use response surface approaches such
as linear regression surfaces [31] and Gaussian process
modeling [41] to reduce the required number of runs. The
response surface methods can be also combined with the
sample size approach applied in this paper from O’Hagan
et al. [39]. Future studies can compare these approaches
in terms of their performances in estimating uncertainty
intervals for MS models within a ﬁxed computational time.
It is worth emphasizing that the results of UA should be
interpreted as conditional on the assumptions involved in
performing this analysis. For example, ignoring the struc-
tural uncertainty should be reported in conjunction with the
resulting uncertainty intervals. In addition, the sample size
(population size and the number of runs) and the precision
level used in sample size calculations should be reported.
In the example of UA provided in Section 4,w eh a v e
implemented the proposed approach for POHEM-OA. The
resultant 95% uncertainty intervals incorporate the uncer-
tainty associated with the hazard ratios for the eﬀect of BMI
on OA risk and use bootstraps to include the BMI trajectory
model parameters. By adopting the sample size approach
developed by O’Hagan et al. [39], we were able to reduce the
computational time from 12 days to 12 hours, with the same
level of precision for the uncertainty intervals.
The UA approach described in this study is not free
of limitations. One limitation is that methods speciﬁc to
agent-based models with interindividual interactions were
not addressed. However, our approach can be generalized
to include such models in future studies. Another limitation
is that we only addressed two sources of uncertainty, MC
error and parameter uncertainty. Other sources, speciﬁcally,
uncertainty due to model structure and sources of data, have
been ignored. Draper [69] discussed the Bayesian approach
for structural uncertainty and demonstrated how alternative
statistical model structures, such as functional forms for
dose-response relationships or alternative link function for
generalizedlinearmodels,canbeincludedintheUA.Berryet
al.[16]performedthistypeofstructuralUAforbreastcancer
models developed by CISNET. CISNET consists of seven
model development groups who work independently butEpidemiology Research International 11
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Figure 3: Results of uncertainty analysis: sex-speciﬁc prevalence of osteoarthritis (OA) in Canada during (2001–2021) as predicted by
POHEM-OA; curves inside the graphs represent the mean estimate surrounded by 95% uncertainty intervals. POHEM-OA: Population
Health Microsimulation model for osteoarthritis (OA) [46].
with the same standardized calibration data and protocols.
The authors regarded outcomes from the seven models to
be a sample from a larger population of possible model
results and used kernel density estimation, a nonparametric
approach, to estimate the probability density function of
the outcome that includes model uncertainty [16]. However,
individual models in CISNET that used MS framework were
not subjected to systematic UA. As noted in Rutter et al.
[13] for MS models with health outcomes and Poulter et al.
[32] for environmental risk assessment models, performing
quantitative UA for structural uncertainty is feasible only
when all model developers use the same data input and
cooperate to simulate and present the outcome. Unless
such cooperation between model developers can be assured,
structural uncertainty should be approached in the model
validation process through scenario analyses, rather than
being incorporated into the quantitative UA [32].
We have approached the UA from the traditional statis-
tical viewpoint, the frequentist statistics, which begins with
the assumption that the factors to be estimated are unknown
constants. In contrast, Bayesian inferences begin with the
assumption that every parameter is stochastic [42, 69]. As
such, they directly incorporate uncertainty of the outcome
in a simulation model. Bayesian methods incorporating
Markov Chain Monte Carlo (MCMC) are increasingly used
to model correlated parameters in UA instead of bootstrap-
based methods or parametric distributions discussed here
[68, 69].
Finally, it should be noted that UA is a prerequisite for
“value of information analysis” in decision-analytic models
[33, 47] or stochastic “sensitivity analysis (SA)” as deﬁned
in environmental models [32], where contribution of each
parameter to the total uncertainty of the model is being
estimated[45,70].SAandUAarewarrantedwhenadecision
must be made about whether to expand resources to acquire
additional information with regard to input parameters of
the simulation model. In general, the greater the uncertainty
of the outcome, the greater the expected values of additional
information gained by future research [47]. UA can be used
to estimate the sensitivity indices of each parameter [45]t o
determine the value of collecting additional data in order
to improve the accuracy of the model’s prediction [33, 70].
Future studies should be directed toward providing methods
of stochastic SA in PMS models.
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